Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1

Yuning Xiong, Kathleen A. Donovan, Michael P. Kline, Michael K. Gornet, Laurie L. Moon-Tasson, Martha Lacy, Angela Dispenzieri, Morie Gertz, Philip R. Greipp, John A. Lust

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Interleukin-1β (IL-1β) is abnormally expressed by the plasma cells obtained from myeloma patients, and it is a potent inducer of the important myeloma growth factor, IL-6. We investigated whether levels of IL-1β biologic activity might distinguish different groups of patients with smoldering multiple myeloma (SMM). We measured the ability of IL-6 production by bone marrow stromal cells to serve as a surrogate marker for IL-1β biologic activity. Using this IL-1β bioassay, we found that it is sensitive at <1 pg/ml of recombinant IL-1β and that IL-1β biologic activity is detectable with either mature or pro-IL-1β-transduced myeloma cell lines. Patients with active myeloma induced quantitatively higher levels of stromal cell IL-6 production when compared with those with monoclonal gammopathy of undetermined significance (MGUS). The bioassay distinguished two groups of SMM patients, those who were high producers, similar to patients with active MM, and those who were low producers, comparable to MGUS patients. IL-1 antagonists inhibited the paracrine IL-6 production by ≥90% in the majority of patients with an elevated IL-6 level. Based on such studies, it may be possible to predict patients that will progress to active MM and to delay or prevent this progression with IL-1 antagonists.

Original languageEnglish (US)
Pages (from-to)83-95
Number of pages13
JournalJournal of Interferon and Cytokine Research
Volume26
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Social Identification
Multiple Myeloma
Interleukin-1
Interleukin-6
Monoclonal Gammopathy of Undetermined Significance
Biological Assay
Aptitude
Stromal Cells
Mesenchymal Stromal Cells
Intercellular Signaling Peptides and Proteins
Biomarkers
Cell Line

ASJC Scopus subject areas

  • Cell Biology
  • Immunology
  • Virology

Cite this

Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. / Xiong, Yuning; Donovan, Kathleen A.; Kline, Michael P.; Gornet, Michael K.; Moon-Tasson, Laurie L.; Lacy, Martha; Dispenzieri, Angela; Gertz, Morie; Greipp, Philip R.; Lust, John A.

In: Journal of Interferon and Cytokine Research, Vol. 26, No. 2, 02.2006, p. 83-95.

Research output: Contribution to journalArticle

Xiong, Yuning ; Donovan, Kathleen A. ; Kline, Michael P. ; Gornet, Michael K. ; Moon-Tasson, Laurie L. ; Lacy, Martha ; Dispenzieri, Angela ; Gertz, Morie ; Greipp, Philip R. ; Lust, John A. / Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. In: Journal of Interferon and Cytokine Research. 2006 ; Vol. 26, No. 2. pp. 83-95.
@article{45740a2e37a84576aa838fb5528cf1a1,
title = "Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1",
abstract = "Interleukin-1β (IL-1β) is abnormally expressed by the plasma cells obtained from myeloma patients, and it is a potent inducer of the important myeloma growth factor, IL-6. We investigated whether levels of IL-1β biologic activity might distinguish different groups of patients with smoldering multiple myeloma (SMM). We measured the ability of IL-6 production by bone marrow stromal cells to serve as a surrogate marker for IL-1β biologic activity. Using this IL-1β bioassay, we found that it is sensitive at <1 pg/ml of recombinant IL-1β and that IL-1β biologic activity is detectable with either mature or pro-IL-1β-transduced myeloma cell lines. Patients with active myeloma induced quantitatively higher levels of stromal cell IL-6 production when compared with those with monoclonal gammopathy of undetermined significance (MGUS). The bioassay distinguished two groups of SMM patients, those who were high producers, similar to patients with active MM, and those who were low producers, comparable to MGUS patients. IL-1 antagonists inhibited the paracrine IL-6 production by ≥90{\%} in the majority of patients with an elevated IL-6 level. Based on such studies, it may be possible to predict patients that will progress to active MM and to delay or prevent this progression with IL-1 antagonists.",
author = "Yuning Xiong and Donovan, {Kathleen A.} and Kline, {Michael P.} and Gornet, {Michael K.} and Moon-Tasson, {Laurie L.} and Martha Lacy and Angela Dispenzieri and Morie Gertz and Greipp, {Philip R.} and Lust, {John A.}",
year = "2006",
month = "2",
doi = "10.1089/jir.2006.26.83",
language = "English (US)",
volume = "26",
pages = "83--95",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1

AU - Xiong, Yuning

AU - Donovan, Kathleen A.

AU - Kline, Michael P.

AU - Gornet, Michael K.

AU - Moon-Tasson, Laurie L.

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Gertz, Morie

AU - Greipp, Philip R.

AU - Lust, John A.

PY - 2006/2

Y1 - 2006/2

N2 - Interleukin-1β (IL-1β) is abnormally expressed by the plasma cells obtained from myeloma patients, and it is a potent inducer of the important myeloma growth factor, IL-6. We investigated whether levels of IL-1β biologic activity might distinguish different groups of patients with smoldering multiple myeloma (SMM). We measured the ability of IL-6 production by bone marrow stromal cells to serve as a surrogate marker for IL-1β biologic activity. Using this IL-1β bioassay, we found that it is sensitive at <1 pg/ml of recombinant IL-1β and that IL-1β biologic activity is detectable with either mature or pro-IL-1β-transduced myeloma cell lines. Patients with active myeloma induced quantitatively higher levels of stromal cell IL-6 production when compared with those with monoclonal gammopathy of undetermined significance (MGUS). The bioassay distinguished two groups of SMM patients, those who were high producers, similar to patients with active MM, and those who were low producers, comparable to MGUS patients. IL-1 antagonists inhibited the paracrine IL-6 production by ≥90% in the majority of patients with an elevated IL-6 level. Based on such studies, it may be possible to predict patients that will progress to active MM and to delay or prevent this progression with IL-1 antagonists.

AB - Interleukin-1β (IL-1β) is abnormally expressed by the plasma cells obtained from myeloma patients, and it is a potent inducer of the important myeloma growth factor, IL-6. We investigated whether levels of IL-1β biologic activity might distinguish different groups of patients with smoldering multiple myeloma (SMM). We measured the ability of IL-6 production by bone marrow stromal cells to serve as a surrogate marker for IL-1β biologic activity. Using this IL-1β bioassay, we found that it is sensitive at <1 pg/ml of recombinant IL-1β and that IL-1β biologic activity is detectable with either mature or pro-IL-1β-transduced myeloma cell lines. Patients with active myeloma induced quantitatively higher levels of stromal cell IL-6 production when compared with those with monoclonal gammopathy of undetermined significance (MGUS). The bioassay distinguished two groups of SMM patients, those who were high producers, similar to patients with active MM, and those who were low producers, comparable to MGUS patients. IL-1 antagonists inhibited the paracrine IL-6 production by ≥90% in the majority of patients with an elevated IL-6 level. Based on such studies, it may be possible to predict patients that will progress to active MM and to delay or prevent this progression with IL-1 antagonists.

UR - http://www.scopus.com/inward/record.url?scp=33644844811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644844811&partnerID=8YFLogxK

U2 - 10.1089/jir.2006.26.83

DO - 10.1089/jir.2006.26.83

M3 - Article

C2 - 16487028

AN - SCOPUS:33644844811

VL - 26

SP - 83

EP - 95

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 2

ER -